Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Tryptophan catabolism by indoleamine 2,3-dioxygenase (IDO1) is a physiological immunoregulatory mechanism often hijacked by tumors. Our recent extensive study of IDO1 protein expression in human tissues showed expression in mature dendritic cells and in pulmonary and placental endothelial cells. IDO1 was also expressed in 56% of tumors, either by tumoral, stromal, or endothelial cells. These results and reagent will guide the clinical development of IDO1 inhibitors for cancer therapy.

Original publication

DOI

10.1080/2162402x.2014.1003012

Type

Journal article

Journal

Oncoimmunology

Publication Date

05/2015

Volume

4

Pages

e1003012 - e1003012

Addresses

Ludwig Institute for Cancer Research ; Brussels, Belgium ; WELBIO (Walloon Excellence in Life Sciences and Biotechnology) ; Brussels, Belgium ; de Duve Institute, Université catholique de Louvain , Brussels, Belgium.